Showing results filtered by:
254 Results
Opportunistic fungal infections represent major causes of morbidity and mortality despite the administration of antifungal therapy. A better mechanistic understanding of host-fungal interactions will inform the development of improved immune-based strategies for the prevention, risk stratification, prognostication, vaccination, and treatment of vulnerable patient populations. In the Fungal
Last Reviewed: February 18, 2025
The Division of Intramural Research (DIR), a component of the National Institute of Allergy and Infectious Diseases, has long been at the forefront of research on immunologic, allergic, and infectious diseases. For more than 60 years, DIR scientists have discovered new pathogens, deciphered normal immune system function, identified aberrations underlying immunological diseases, and developed FDA
Last Reviewed: June 6, 2024
LMIV Vaccine Development Unit develops and performs clinical evaluation of prototype malaria vaccines. The VDU focuses on research to eradicate malaria through development of a vaccine to interrupt malaria transmission, including transmission-blocking components and pre-erythrocytic components. The VDU also designs and develops vaccines specifically to protect pregnant women and their infants.
Last Reviewed: November 21, 2022
The 206 th meeting of the National Advisory Allergy and Infectious Diseases Council (NAAIDC) convened virtually at 10:30 a.m. on Tuesday, January 30, 2024. Dr. Jeanne Marrazzo, Director, National Institute of Allergy and Infectious Diseases (NIAID) presided as chair. In accordance with the provisions of Public Law 92-463, the meeting was open to the public from 10:30 a.m. to 11:45 a.m. and from 1
Last Reviewed: May 21, 2024